Alnylam Pharmaceuticals, Inc. (ALNY Quick QuoteALNY - Free Report) was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $114.49 to $124.86 in the past one-month time frame.

The move came after the leading RNAi therapeutics company announced complete positive results from the APOLLO Phase 3 study for patients with hereditary ATTR amyloidosis with polyneuropathy.

The company has seen one negative estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Alnylam Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Alnylam Pharmaceuticals, Inc. Price

 

Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Ligand Pharmaceuticals Incorporated (LGND Quick QuoteLGND - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ALNY going up? Or down? Predict to see what others think:Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>